File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib

TitleMolecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib
Authors
KeywordsAngiogenesis
Chemotherapy
Hepatocellular carcinoma
Molecular targeted therapy
Issue Date2010
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop
Citation
Expert Opinion On Pharmacotherapy, 2010, v. 11 n. 13, p. 2187-2198 How to Cite?
AbstractImportance of the field: With the recent advances in the knowledge of molecular biology of hepatocellular carcinoma (HCC), there have been encouraging developments in targeted therapy for advanced HCC. Areas covered in this review: This review discusses the development of targeted therapy for advanced HCC patient since 2006. Among the newly identified targets, promising results have been shown in targeting the anti-angiogenic pathway. Pure anti-angiogenic agents such as bevacizumab and PTK 787 demonstrate modest activity in treating patients with advanced HCC. Sorafenib, a multi-targeted tyrosine kinase inhibitor with both anti-angiogenic and anti-proliferative effects, has been shown to prolong the overall survival of patients with advanced HCC in two Phase III randomized trials. Like sorafenib, other anti-angiogenic multi-targeted tyrosine kinase inhibitors, such as sunitinib, pazopanib, brivanib and linifanib, also show promising activity in various stages of clinical trials. Other on-going early-phase studies are exploring the activities of drugs targeting novel pathways, such as PI3K/AKT/m TOR, hepatocyte growth factor/mesenchymal epithelial transition factor and insulin-like growth factor. What the reader will gain: After reading this review, the reader should have an in-depth understanding of the latest developments in the molecular targeted therapy of advanced HCC. Take home message: The development of sorafenib in the treatment of advanced HCC proves the concept that molecular targeted therapies, especially anti-angiogenic agents, play a pivotal role in the treatment of this otherwise chemoresistant neoplasm. Future progress depends on further unraveling more molecular mechanisms of HCC for therapeutic intervention. © 2010 Informa UK, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/132639
ISSN
2015 Impact Factor: 3.543
2015 SCImago Journal Rankings: 0.884
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_HK
dc.contributor.authorPang, Ren_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorPoon, RTen_HK
dc.date.accessioned2011-03-28T09:27:17Z-
dc.date.available2011-03-28T09:27:17Z-
dc.date.issued2010en_HK
dc.identifier.citationExpert Opinion On Pharmacotherapy, 2010, v. 11 n. 13, p. 2187-2198en_HK
dc.identifier.issn1465-6566en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132639-
dc.description.abstractImportance of the field: With the recent advances in the knowledge of molecular biology of hepatocellular carcinoma (HCC), there have been encouraging developments in targeted therapy for advanced HCC. Areas covered in this review: This review discusses the development of targeted therapy for advanced HCC patient since 2006. Among the newly identified targets, promising results have been shown in targeting the anti-angiogenic pathway. Pure anti-angiogenic agents such as bevacizumab and PTK 787 demonstrate modest activity in treating patients with advanced HCC. Sorafenib, a multi-targeted tyrosine kinase inhibitor with both anti-angiogenic and anti-proliferative effects, has been shown to prolong the overall survival of patients with advanced HCC in two Phase III randomized trials. Like sorafenib, other anti-angiogenic multi-targeted tyrosine kinase inhibitors, such as sunitinib, pazopanib, brivanib and linifanib, also show promising activity in various stages of clinical trials. Other on-going early-phase studies are exploring the activities of drugs targeting novel pathways, such as PI3K/AKT/m TOR, hepatocyte growth factor/mesenchymal epithelial transition factor and insulin-like growth factor. What the reader will gain: After reading this review, the reader should have an in-depth understanding of the latest developments in the molecular targeted therapy of advanced HCC. Take home message: The development of sorafenib in the treatment of advanced HCC proves the concept that molecular targeted therapies, especially anti-angiogenic agents, play a pivotal role in the treatment of this otherwise chemoresistant neoplasm. Future progress depends on further unraveling more molecular mechanisms of HCC for therapeutic intervention. © 2010 Informa UK, Ltd.en_HK
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eopen_HK
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_HK
dc.rightsExpert Opinion on Pharmacotherapy. Copyright © Informa Healthcare.-
dc.subjectAngiogenesisen_HK
dc.subjectChemotherapyen_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectMolecular targeted therapyen_HK
dc.titleMolecular targeted therapy of advanced hepatocellular carcinoma beyond sorafeniben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1465-6566&volume=11&issue=13&spage=2187&epage=2198&date=2010&atitle=Molecular+targeted+therapy+of+advanced+hepatocellular+carcinoma+beyond+sorafenib-
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.emailPang, R: robertap@hkucc.hku.hken_HK
dc.identifier.emailPoon, RT: poontp@hkucc.hku.hken_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.identifier.authorityPang, R=rp00274en_HK
dc.identifier.authorityPoon, RT=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14656561003724705en_HK
dc.identifier.pmid20707757-
dc.identifier.scopuseid_2-s2.0-77955817977en_HK
dc.identifier.hkuros185924-
dc.identifier.hkuros178977-
dc.identifier.hkuros183832-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77955817977&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume11en_HK
dc.identifier.issue13en_HK
dc.identifier.spage2187en_HK
dc.identifier.epage2198en_HK
dc.identifier.isiWOS:000281774900007-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.scopusauthoridPang, R=7004376659en_HK
dc.identifier.scopusauthoridChan, P=7403497841en_HK
dc.identifier.scopusauthoridPoon, RT=7103097223en_HK
dc.identifier.citeulike7781967-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats